

Listing of Claims :

1- 64. (Canceled)

65. (Previously Presented) A pharmaceutical formulation in unit dosage form comprising per dose unit an amount of active ingredient within the range from about 5 mg to about 60 mg of 6-methoxy-2-[(S)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in pure form, or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof, wherein said formulation in unit dosage form being adapted for oral administration in the form of a capsule or tablet.

66. (Previously Presented) A pharmaceutical formulation according to claim 65 wherein said capsule or tablet is enterically coated.

67. (Previously Presented) A pharmaceutical formulation according to claim 66 in a form adapted for administration to treat gastric acid related diseases in mammals.

68. (Previously Presented) A pharmaceutical formulation according to claim 66 wherein said amount of active ingredient in said unit dosage form is selected from the group consisting of about 10 mg, 20 mg, and 40 mg.

69. (Previously Presented) A pharmaceutical formulation according to claim 66 further comprising a metal cation, wherein the metal cation is magnesium.

70. (Previously Presented) A pharmaceutical formulation in unit dosage form comprising per dosage unit an amount of active ingredient within the range from about 5 mg to about 60 mg of 6-methoxy-2-[(S)-(4-methoxy-3,5-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof which is essentially free of 5-methoxy-2-[(S)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, wherein said formulation in unit dosage form being adapted for oral administration in the form of a capsule or tablet.

71. (Previously Presented) A pharmaceutical formulation according to claim 70 wherein said capsule or tablet is enterically coated.

72. (Previously Presented) A pharmaceutical formulation according to claim 71 in a form adapted for administration to treat gastric acid related diseases in mammals.

73. (Previously Presented) A pharmaceutical formulation according to claim 71 wherein said amount of active ingredient in said unit dosage form is selected from the group consisting of about 10 mg, 20 mg, and 40 mg.

74. (Previously Presented) A pharmaceutical formulation according to claim 71 further comprising a metal cation, wherein the metal cation is magnesium.

75. (Previously Presented) A pharmaceutical formulation in unit dosage form comprising per dosage unit an amount of active ingredient within the range from about 5 mg to about 60 mg of a composition comprising 6-methoxy-2-[[*(S*)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole and 5-methoxy-2-[[*(S*)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof, wherein the 6-methoxy-2-[[*(S*)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole is present in said composition in an amount from about 96% to about 100% (w/w), wherein said formulation in unit dosage form being adapted for oral administration in the form of a capsule or tablet.

76. (Previously Presented) A pharmaceutical formulation according to claim 75 wherein said capsule or tablet is enterically coated.

77. (Previously Presented) A pharmaceutical formulation according to claim 76 in a form adapted for administration to treat gastric acid related diseases in mammals.

78. (Previously Presented) A pharmaceutical formulation according to claim 76 wherein said amount of active ingredient in said dosage unit form is selected from the group consisting of about 10 mg, 20 mg, and 40 mg.

79. (Previously Presented) A pharmaceutical formulation according to claim 71 further comprising a metal cation, wherein the metal cation is magnesium.

80. (Previously Presented) A pharmaceutical formulation in unit dosage form comprising per dosage unit an amount of active ingredient within the range from about 5 mg to about 60 mg of a composition comprising 6-methoxy-2-[[*(S*)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole and 5-methoxy-2-[[*(S*)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole or pharmaceutically acceptable salts, solvates, hydrates, or combinations thereof, wherein the 6-methoxy-2-[[*(S*)-(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole is present in said composition in an amount from about 0% to about 89% (w/w), wherein said formulation in unit dosage form being adapted for oral administration in the form of a capsule or tablet.

81. (Previously Presented) A pharmaceutical formulation according to claim 80 wherein said capsule or tablet is enterically coated.

82. (Previously Presented) A pharmaceutical formulation according to claim 81 in a form adapted for administration to treat gastric acid related diseases in mammals.

83. (Previously Presented) A pharmaceutical formulation according to claim 81 wherein said amount of active ingredient in said dosage unit form is selected from the group consisting of about 10 mg, 20 mg, and 40 mg.

84. (Previously Presented) A pharmaceutical formulation according to claim 81 further comprising a metal cation, wherein the metal cation is magnesium.